<DOC>
	<DOCNO>NCT00731549</DOCNO>
	<brief_summary>To evaluate overall effectiveness aripiprazole intramuscular ( IM ) depot maintenance treatment patient schizophrenia .</brief_summary>
	<brief_title>Intramuscular Depot Formulation Aripiprazole Maintenance Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>This open-label , uncontrolled study enroll subject Phase 4 Study 31-07-246 Phase 3 Study 31- 07-247 new subject participate Studies 246/247 . The treatment history subject prior enrollment open-label study vary accord design pivotal double-blind study ( i.e. , 31-07-246 31-07-247 ) . This open-label study comprise phase similar pivotal double-blind study ( i.e. , Studies 246/247 ) : screening phase ( applicable ) , conversion phase ( Phase 1 , applicable ) , oral stabilization phase ( Phase 2 ) , IM depot open-label maintenance phase ( Phase 3 ) . Phase 3 52-week treatment period 26-week follow-up period . During Phase 3 ( open-label maintenance phase ) oral aripiprazole rescue medication allow subject meet stability criterion meet criterion impend relapse/exacerbation psychotic symptom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Subjects able provide write informed consent and/or consent obtain legally acceptable representative ( require IRB/IEC ) , prior initiation protocolrequired procedure . Male female subject 18 65 year age , inclusive , time informed consent . Subjects complete Studies 246/247 withdraw doubleblind maintenance phase either study ( Phase 4 Study 246 Phase 3 Study 247 ) , new subject participate Studies 246/247 . # Subjects , investigator 's judgment , require chronic treatment antipsychotic medication . Subjects able understand nature study follow protocol requirement , include prescribed dosage regimen , tablet ingestion , IM depot injection , discontinuation prohibit concomitant medication , read understand write word order complete patientreported outcome measure , reliably rat assessment scale . Subjects current DSMIVTR diagnosis schizophrenia , include schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid antisocial personality disorder . Subjects schizophrenia consider resistant/refractory antipsychotic treatment history response clozapine . Subjects significant risk violent behavior significant risk commit suicide base history investigator 's judgment . Subjects currently meet DSMIVTR criterion substance dependence ; include alcohol benzodiazepine , exclude caffeine nicotine , two positive drug screen cocaine . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones . Subjects history hypersensitivity antipsychotic agent . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>IM Depot</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Intramuscular</keyword>
</DOC>